2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Elizabeth Plimack, MD, MS, reviews key genitourinary cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Genitourinary Cancers

Significant survival benefit and favorable safety profile with pembrolizumab vs chemotherapy maintained in extended follow-up.

Released: June 9, 2017

ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.

Released: June 8, 2017

In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.

Released: June 14, 2017

Adjuvant pazopanib at 600 mg after nephrectomy did not prolong DFS compared with placebo in patients with locally advanced RCC.

Released: June 13, 2017

Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.

Released: June 8, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.